Tailstorm Health (Medivant Health) sterile compounded drugs had insanitary conditions and current good manufacturing practice failures, prompting a bevacizumab recall.
What happened
FDA inspected the facility from September 24, 2024, to October 10, 2024, and found sterile drug products prepared under insanitary conditions plus current good manufacturing practice (CGMP) violations, including inadequate evaluation after microbial contamination in the aseptic processing area and inadequate dynamic smoke studies. The investigator also found failures to investigate batch discrepancies and inadequate environmental monitoring, and the letter cites section 503B labeling and adverse event reporting problems. The firm recalled six bevacizumab lots due to lack of sterility assurance.
What FDA found
FDA observed that the firm did not adequately evaluate product and take corrective action after microbial contamination was recovered in the aseptic processing area.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]FDA observed that the firm failed to perform adequate smoke studies under dynamic conditions to show unidirectional airflow in the aseptic processing area.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm failed to thoroughly investigate unexplained discrepancies or failures of a batch or component to meet specifications.
21 CFR 211.192The firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.
21 CFR 211.42(c)(10)(iv)Labels for Semaglutide Injection 1mg/0.2ml and Tirzepatide Injection 2.5mg/0.5ml did not include "Office Use Only."
FDCA section 503B(a)(10) [21 U.S.C. § 353b(a)(10)]The firm's adverse event reporting procedures were inadequate because they did not define "unexpected" events and did not provide for reporting through FDA's Safety Reporting Portal or Electronic Submission Gateway.
21 CFR 310.305(b), (e)
What FDA wants
FDA asks the company to notify the office in writing within 15 working days of the specific steps taken to address the violations, with explanations and supporting documentation. If it cannot fully address the matter in that time, it must state the reason for delay and the time within which it will do so.
Who should pay attention
- hospitals and clinics that buy sterile compounded drugs
- brands or pharmacies relying on Medivant as an outsourcing facility
- quality teams at sterile compounding facilities using similar aseptic processes
This is a summary. Read the original letter on fda.gov.